Invitation-only event to discuss and review progress towards improved flu vaccines
Ness Ziona, Israel – August 10, 2016 –
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that it has been invited to participate in the ‘Eighth WHO meeting on the development of influenza vaccines that induce broadly protective and long-lasting immune responses’. The meeting will be held in Chicago, IL on August 23 and 24, 2016.
The Global Vaccine Action Plan (GVAP) aims for at least one licensed universal influenza vaccine by 2020. The World Health Organization (WHO) Initiative for Vaccine Research monitors progress toward the achievement of GVAP goals
through consultations of experts in the field. Having completed 5 clinical trials, and with two ongoing Phase 2 trials sponsored by the EU’s UNISEC and the US NIH/DMID, BiondVax’s M-001 is recognized as a leading universal flu vaccine candidate. M-001’s clinical trial results have shown safety and immunogenicity in both young and elderly adults against a broad range of seasonal and pandemic flu strains.
Joshua Phillipson, BiondVax’s Head of Business Development, commented, “The meeting’s participants, leading public health and influenza experts, recognize the urgent need for a next generation flu vaccine that broadly protects against future seasonal and pandemic flu strains. Current solutions fall short. BiondVax’s vaccine candidate is unique in that it’s in advanced human clinical trials, and is designed to be a ‘one size fits all’ flu vaccine. It can be used year round, and stockpiled for future pandemics. I’m looking forward to meeting with our colleagues and contributing to the discussion at the upcoming WHO meeting.”
BiondVax will be participating along with representatives from WHO, NIH, BARDA, and other leading industry experts.
For more information about the WHO meeting, please see http://who.int/immunization/research/meetings_workshops/8th_influenza_vaccine_chicago2016/en/.